Ocular Therapeutix Inc. (NASDAQ:OCUL) went down by -2.00% from its latest closing price compared to the recent 1-year high of $12.42. The company’s stock price has collected -8.61% of loss in the last five trading sessions. Press Release reported on 10/14/20 that Ocular Therapeutix(TM) Announces Pricing of Public Offering of Common Stock
Is It Worth Investing in Ocular Therapeutix Inc. (NASDAQ :OCUL) Right Now?
Plus, the 36-month beta value for OCUL is at 1.87. Opinions of the stock are interesting as 5 analysts out of 6 who provided ratings for Ocular Therapeutix Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 1 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $12.67, which is $2.37 above the current price. OCUL currently public float of 55.11M and currently shorts hold a 12.58% ratio of that float. Today, the average trading volume of OCUL was 1.01M shares.
OCUL’s Market Performance
OCUL stocks went down by -8.61% for the week, with a monthly jump of 16.38% and a quarterly performance of 16.12%, while its annual performance rate touched 196.83%. The volatility ratio for the week stands at 9.75% while the volatility levels for the past 30 days are set at 7.91% for Ocular Therapeutix Inc.. The simple moving average for the period of the last 20 days is 11.44% for OCUL stocks with a simple moving average of 50.86% for the last 200 days.
Analysts’ Opinion of OCUL
Many brokerage firms have already submitted their reports for OCUL stocks, with H.C. Wainwright repeating the rating for OCUL by listing it as a “Buy.” The predicted price for OCUL in the upcoming period, according to H.C. Wainwright is $13 based on the research report published on August 10th of the current year 2020.
H.C. Wainwright gave a rating of “Buy” to OCUL, setting the target price at $9 in the report published on May 21st of the previous year.
OCUL Trading at 17.62% from the 50-Day Moving Average
After a stumble in the market that brought OCUL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -17.07% of loss for the given period.
Volatility was left at 7.91%, however, over the last 30 days, the volatility rate increased by 9.75%, as shares surge +11.47% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +21.75% upper at present.
During the last 5 trading sessions, OCUL fell by -8.61%, which changed the moving average for the period of 200-days by +160.76% in comparison to the 20-day moving average, which settled at $9.30. In addition, Ocular Therapeutix Inc. saw 160.76% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at OCUL starting from SUMMER ROAD LLC, who purchase 363,636 shares at the price of $5.50 back on May 19. After this action, SUMMER ROAD LLC now owns 5,618,424 shares of Ocular Therapeutix Inc., valued at $1,999,998 using the latest closing price.
SUMMER ROAD LLC, the 10% Owner of Ocular Therapeutix Inc., purchase 35,052 shares at $4.87 during a trade that took place back on Mar 24, which means that SUMMER ROAD LLC is holding 5,254,788 shares at $170,714 based on the most recent closing price.
Stock Fundamentals for OCUL
Current profitability levels for the company are sitting at:
- -2029.86 for the present operating margin
- +15.07 for the gross margin
The net margin for Ocular Therapeutix Inc. stands at -2043.34. The total capital return value is set at -147.46, while invested capital returns managed to touch -149.89.
When we switch over and look at the enterrpise to sales, we see a ratio of 43.47, with the company’s debt to enterprise value settled at 0.32. The receivables turnover for the company is 3.08 and the total asset turnover is 0.06. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.00.